Raj Nitya, Valentino Emily, Capanu Marinela, Tang Laura H, Basturk Olca, Untch Brian R, Allen Peter J, Klimstra David S, Reidy-Lagunes Diane
From the Departments of *Medicine, †Biostatistics, ‡Pathology, and §Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Pancreas. 2017 Mar;46(3):296-301. doi: 10.1097/MPA.0000000000000735.
Emerging data suggest that not all grade 3 (G3) pancreatic neuroendocrine neoplasms (panNENs) behave the same; tumor differentiation may predict outcome.
Patients with G3 panNENs treated at our institution between 1999 and 2014 were identified. Demographics, response to therapy, and overall survival were determined.
Forty-five patients were identified, 16 with G3 well differentiated pancreatic neuroendocrine tumors (WD-panNETs) and 29 with poorly differentiated neuroendocrine carcinomas (PDNEC). Median overall survival in G3 WD-panNET patients was 52.2 months (95% confidence interval, 19.3-86.9 months) compared with 10.1 months (95% confidence interval, 6.9-12.4 months) in PDNEC patients (P = 0.0009). Response rate to platinum agents was 10% in G3 WD-panNETs and 37% in PDNEC. Response rate to alkylating agents was 50% in G3 WD-panNETs and 50% in PDNEC.
Both G3 WD-panNETs and PDNEC responded to platinum and alkylating agents. Overall survival was significantly greater in G3 WD-panNETs compared with PDNEC. These findings challenge current classification and suggest that G3 panNENs should be classified by morphology.
新出现的数据表明,并非所有3级(G3)胰腺神经内分泌肿瘤(panNENs)的行为都相同;肿瘤分化可能预测预后。
确定1999年至2014年在我们机构接受治疗的G3 panNENs患者。确定人口统计学、对治疗的反应和总生存期。
共确定45例患者,其中16例为G3高分化胰腺神经内分泌肿瘤(WD-panNETs),29例为低分化神经内分泌癌(PDNEC)。G3 WD-panNET患者的中位总生存期为52.2个月(95%置信区间,19.3 - 86.9个月),而PDNEC患者为10.1个月(95%置信区间6.9 - 12.4个月)(P = 0.0009)。G3 WD-panNETs对铂类药物的反应率为10%,PDNEC为37%。G3 WD-panNETs对烷化剂的反应率为50%,PDNEC为50%。
G3 WD-panNETs和PDNEC对铂类和烷化剂均有反应。G3 WD-panNETs的总生存期明显长于PDNEC。这些发现挑战了当前的分类,并表明G3 panNENs应按形态学分类。